RT Journal Article
SR Electronic
T1 Defining high-value information for COVID-19 decision-making
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.06.20052506
DO 10.1101/2020.04.06.20052506
A1 ,
A1 Bilinski, Alyssa
A1 Birger, Ruthie
A1 Burn, Samantha
A1 Chitwood, Melanie
A1 Clarke-Deelder, Emma
A1 Copple, Tyler
A1 Eaton, Jeffrey
A1 Ehrlich, Hanna
A1 Erlendsdottir, Margret
A1 Eshghi, Soheil
A1 Farid, Monica
A1 Fitzpatrick, Meagan
A1 Giardina, John
A1 Gonsalves, Gregg
A1 Hsieh, Yuli Lily
A1 Iloglu, Suzan
A1 Kao, Yu-Han
A1 MacKay, Evan
A1 Menzies, Nick
A1 Mulaney, Bianca
A1 Paltiel, David
A1 Perniciaro, Stephanie
A1 Phillips, Maile
A1 Rich, Katherine
A1 Salomon, Joshua A
A1 Sherak, Raphael
A1 Shioda, Kayoko
A1 Swartwood, Nicole
A1 Testa, Christian
A1 Thornhill, Thomas
A1 White, Elizabeth
A1 Williamson, Anne
A1 York, Anna
A1 Zhu, Jinyi
A1 Zhu, Lin
YR 2020
UL http://medrxiv.org/content/early/2020/04/08/2020.04.06.20052506.abstract
AB Initial projections from the first generation of COVID-19 models focused public attention on worst-case scenarios in the absence of decisive policy action. These underscored the imperative for strong and immediate measures to slow the spread of infection. In the coming weeks, however, as policymakers continue enlisting models to inform decisions on COVID-19, answers to the most difficult and pressing policy questions will be much more sensitive to underlying uncertainties. In this study, we demonstrate a model-based approach to assessing the potential value of reducing critical uncertainties most salient to COVID-19 decision-making and discuss priorities for acquiring new data to reduce these uncertainties. We demonstrate how information about the impact of non-pharmaceutical interventions could narrow prediction intervals around hospitalizations over the next few weeks, while information about the prevalence of undetected cases could narrow prediction intervals around the timing and height of the peak of the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementC-SPEC does not have institutional funding. C-SPEC member funding is provided in its authorship list.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code is available on GitHub.